系统性免疫抑制疗法在异常非传染性紫外炎和硬化症:疾病缓解,停止和复发模式
Ana Margarida Ferreira1,2, Marta Inês Silva3, Ana Catarina Pedrosa3,4
1Department of Ophthalmology, ULS São João, Porto, Portugal. amargaridapferreira@gmail.com.
概括
免疫抑制疗法 (IST) 有效治疗非传染性脑膜炎和硬化炎,早期控制和持续治疗与持久缓解有关. 延迟缓解和更短的IST持续时间预测这些眼部炎症状况的复发.
科学领域:
- 眼科医生 眼科 眼科
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
背景情况:
- 当局部治疗失败时,异形非传染性脑膜炎和硬化症往往需要免疫抑制疗法 (IST).
- 在这些条件下,IST的长期结果和复发预测因素尚未完全理解.
研究的目的:
- 评估只有眼部的非传染性紫外炎或硬化症患者的IST长期结果.
- 为了确定IST戒断后缓解和复发的预测因素.
主要方法:
- 110名接受IST治疗非传染性脑膜炎或无系统性疾病的硬化炎的患者的回顾性评估.
- 根据解剖学亚型分析缓解的时间,治疗持续时间和复发率.
- 多变量Cox和后勤回归模型用于评估缓解和复发的预测因素.
主要成果:
- 79%的患者通过一线IST实现了缓解;缓解的中位时间为7个月.
- 后膜炎需要更长的缓解时间 (11个月). 对皮质类固醇的需要与缓缓缓解相关.
- 在IST戒断后,复发发生在27%,通常在10个月内. 更长的缓解时间和更短的IST持续时间预测复发.
结论:
- IST在实现缓解和降低只发生在眼部的非传染性炎症的复发率方面是有效的.
- 早期疾病控制 (6个月内) 和IST持续时间 (≥2年) 与持久缓解有关.
- 后来的参与,需要用皮质类固醇,缓解缓解和更短的IST持续时间表明疾病的严重程度更大,并预测复发.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
480
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
480
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
425
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
425
Inflammatory Bowel Disease IV: Pharmacological Management
471
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
471
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
478
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
478
Nephrotic Syndrome II : Assessment and Medical Management
192
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
192
Drugs for Treatment of Ulcerative Colitis in IBD
449
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
449


